An objective perspective on recombinant hirudin: a new anticoagulant and antithrombotic agent
Research article published in Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis (1991)
Abstract
Leeches have been in medical use for many years. Hirudin, the anticoagulant obtained from the medicinal leech has been purified, characterized and can now be produced by recombinant (r) technology. R-hirudin is a potent inhibitor of thrombin and is therefore a potentially valuable anticoagulant and antithrombotic drug. This article reviews the current status of r-hirudin in this role and compares the pharmacokinetics, mechanism of action and clinical efficacy of this agent with heparin. The methods available for laboratory assessment and clinical monitoring of r-hirudin and the possible ways of antagonizing its effects are also discussed. Finally, the potential clinical applications of r-hirudin are outlined, although further laboratory and clinical studies, together with a fall in the cost of this compound are required before r-hirudin can be more widely accepted as an anticoagulant and antithrombotic agent.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Резюме
Leeches have been in medical use for many years. Hirudin, the anticoagulant obtained from the medicinal leech has been purified, characterized and can now be produced by recombinant (r) technology.
Почему это важно для гирудотерапии
Relevant to the development and clinical application of leech-derived pharmaceutical compounds.
Цитирование
An objective perspective on recombinant hirudin: a new anticoagulant and antithrombotic agent.
Fareed J et al. · Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 1991
Связанный клинический контекст
Узнайте, как это исследование связано с клинической практикой
Добавлено в библиотеку ASH: March 18, 2026 · Последнее обновление сайта: March 18, 2026